Lymphadenopathy secondary prevention: Difference between revisions
Jump to navigation
Jump to search
(Created page with "__NOTOC__ {{Lymphadenopathy}} {{CMG}}; {{AE}} {{ADS}} ==Overview== Effective measures for the secondary prevention of lymphadenopathy include [strategy 1], [strategy 2], and...") |
No edit summary |
||
| Line 16: | Line 16: | ||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
[[Category:Inflammations]] | |||
[[Category:Dermatology]] | |||
[[Category:Medical signs]] | |||
[[Category:Signs and symptoms]] | |||
[[Category:Physical examination]] | |||
[[Category:Up-To-Date]] | |||
[[Category:Oncology]] | |||
[[Category:Medicine]] | |||
[[Category:Infectious disease]] | |||
[[Category:Hematology]] | |||
{{WH}} | {{WH}} | ||
{{WS}} | {{WS}} | ||
Revision as of 16:13, 28 January 2019
|
Lymphadenopathy Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Lymphadenopathy secondary prevention On the Web |
|
American Roentgen Ray Society Images of Lymphadenopathy secondary prevention |
|
Risk calculators and risk factors for Lymphadenopathy secondary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Amandeep Singh M.D.[2]
Overview
Effective measures for the secondary prevention of lymphadenopathy include [strategy 1], [strategy 2], and [strategy 3].
Secondary Prevention
Effective measures for the secondary prevention of lymphadenopathy include:[1]
- [Strategy 1]
- [Strategy 2]
- [Strategy 3]
References
- ↑ Kodama T, Matsuki D, Tada A, Takeda K, Mori S (September 2016). "New concept for the prevention and treatment of metastatic lymph nodes using chemotherapy administered via the lymphatic network". Sci Rep. 6: 32506. doi:10.1038/srep32506. PMID 27581921.